Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Risk Reports
Erschienen in: Current Cardiovascular Risk Reports 2/2010

01.03.2010

Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk

verfasst von: Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Giovanni Mazzotta, Paola Martire, Marta Garofoli, Paolo Verdecchia

Erschienen in: Current Cardiovascular Risk Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Diabetes determines an increased risk of micro- and macrovascular complications, and is associated with a growing disability burden. Although the efficacy of intensive glycemic control in reducing the risk of microvascular complications has been firmly established, a lively debate continues on the relationship between intensive glucose control and macrovascular complications. Recently, the conflicting results of randomized controlled trials designed to evaluate the efficacy of intensive glucose control on cardiovascular disease fueled such debate. While the UKPDS post-trial study and the DCCT/EDIC showed an important “legacy effect” with persistent reductions in cardiovascular disease risk, ADVANCE and VADT found no effect of intensive glucose control on major cardiovascular events. The ACCORD study reported an increased risk for cardiovascular and total mortality associated with intensive glucose control. This review explores the value of intensive therapeutic strategies aimed at lowering indices of glycemic control to near-normal levels on the cardiovascular risk of patients with type 1 and 2 diabetes.
Literatur
1.
Steinbrook R: Facing the diabetes epidemic–mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 2006, 354:545–548.CrossRefPubMed
2.
Gan D: Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2003.
3.
•• Buse JB, Ginsberg HN, Bakris GL, et al.: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007, 115:114–126. In this article, the ADA and American Heart Association attempt to harmonize the recommendations for CVD prevention in people with diabetes.
4.
American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596–615. (Published erratum appears in Diabetes Care 2008, 31:1271.)CrossRef
5.
Wild S, Roglic G, Green A, et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047–1053.CrossRefPubMed
6.
Bunce C, Wormald R: Causes of blind certifications in England and Wales: April 1999–March 2000. Eye (Lond) 2008, 22:905–911.
7.
Tomson C, Ford D, Ansell D: The UK Renal Registry: an overview. Br J Hosp Med (Lond) 2008, 69:548–549.
8.
Centers for Disease Control and Prevention (CDC): Racial differences in trends of end-stage renal disease, by primary diagnosis–United States, 1994–2004. MMWR Morb Mortal Wkly Rep 2007, 56:253–256.
9.
Williamson DF, Vinicor F, Bowman BA; Centers for Disease Control and Prevention Primary Prevention Working Group: Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 2004, 140:951–957.PubMed
10.
Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053–1059. (Published erratum appears in Hypertension 2001, 37:1350.)PubMed
11.
Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570–2581.CrossRefPubMed
12.
Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics–2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69–e171.CrossRefPubMed
13.
Movahed MR, Hashemzadeh M, Jamal MM: Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005, 105:315–318.CrossRefPubMed
14.
Roglic G, Unwin N, Bennett PH, et al.: The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28:2130–2135.CrossRefPubMed
15.
Sowers JR: Treatment of hypertension in patients with diabetes. Arch Intern Med 2004, 164:1850–1857.CrossRefPubMed
16.
Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937–952.CrossRefPubMed
17.
DCCT SG. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977–986.CrossRef
18.
EDIC SG. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381–389. (Published erratum appears in N Engl J Med 2000, 342:1376.)CrossRef
19.
UKPDS SG. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837–853. (Published erratum appears in Lancet 1999, 354:602.)CrossRef
20.
UKPDS SG. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854–865. (Published erratum appears in Lancet 1998, 352:1558.)CrossRef
21.
Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103–117.CrossRefPubMed
22.
•• Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559. In the ACCORD trial, the use of intensive therapy to target normal glycated hemoglobin levels increased mortality and did not significantly reduce major cardiovascular events.
23.
•• Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560–2572. In the ADVANCE trial, intensive glucose control yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy.
24.
Meinert CL, Knatterud GL, Prout TE, Klimt CR: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl):789–830.PubMed
25.
Leibel B: An analysis of the University Group Diabetes Study Program: data results and conclusions. Can Med Assoc J 1971, 105:292–294.PubMed
26.
Karam JH, Matin SB, Forsham PH: Antidiabetic drugs after the University Group Diabetes Program (UGDP). Ann Rev Pharmacol 1975, 15:351–366.CrossRefPubMed
27.
Prout TE, Knatterud GL, Meinert CG: Diabetes drugs: clinical trial. Science 1979, 204:362–363.CrossRefPubMed
28.
•• Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589. This article reports results of the extension phase of the UKPDS study: the legacy effect.
29.
•• Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139. (Published erratum appears in N Engl J Med 2009, 361:1028 and N Engl J Med 2009, 361:1024–1025.) In the VADT trial, intensive glucose control in patients with poorly controlled type 2 diabetes had no significant effect on fatal and nonfatal cardiovascular events.
30.
Bloomgarden ZT: Glycemic control in diabetes: a tale of three studies. Diabetes Care 2008, 31:1913–1919.CrossRefPubMed
31.
Patel A, MacMahon S, Chalmers J, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829–840.CrossRefPubMed
32.
• Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580–591. These are the results of the long-term follow-up of the Steno-2 study.
33.
•• Nathan DM, Zinman B, Cleary PA, et al.: Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983–2005). Arch Intern Med 2009, 169:1307–1316. This article provides the results of the DCCT 30-year follow-up. The frequencies of serious complications in patients with type 1 diabetes mellitus, especially when treated intensively, are lower than reported historically.
34.
•• Kelly TN, Bazzano LA, Fonseca VA, et al.: Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394–403. In this systematic review and meta-analysis of major intervention studies, intensive glucose control does not reduce the risk for cardiovascular death or mortality, and increases the risk for severe hypoglycemia.
35.
• Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765–1772. In this meta-analysis of five intervention studies, intensive glycemic control does not increase mortality risk.
36.
American Diabetes Association: Standards of medical care in diabetes–2009. Diabetes Care 2009, 32(Suppl 1):S13–S61.CrossRef
37.
Adler GK, Bonyhay I, Failing H, et al.: Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes 2009, 58:360–366.CrossRefPubMed
38.
Montori VM, Fernandez-Balsells M: Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009, 150:803–808. (Published erratum appears in Ann Intern Med 2009, 151:144.)PubMed
39.
•• Skyler JS, Bergenstal R, Bonow RO, et al.: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119:351–357. (Published erratum appears in Circulation 2009, 119:e605.) This is the ADA, American College of Cardiology, and American Heart Association joint statement following the publication of ACCORD, ADVANCE, and VADT, recommending less aggressive glycemic targets.
Metadaten
Titel
Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk
verfasst von
Gianpaolo Reboldi
Giorgio Gentile
Fabio Angeli
Giovanni Mazzotta
Paola Martire
Marta Garofoli
Paolo Verdecchia
Publikationsdatum
01.03.2010
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Risk Reports / Ausgabe 2/2010
Print ISSN: 1932-9520
Elektronische ISSN: 1932-9563
DOI
https://doi.org/10.1007/s12170-010-0077-9

Weitere Artikel der Ausgabe 2/2010

Current Cardiovascular Risk Reports 2/2010 Zur Ausgabe

ReviewPaper

Chronic Kidney Disease as a Coronary Heart Disease Risk Equivalent

ReviewPaper

Statin Pharmacogenomics: Lipid Response and Cardiovascular Outcomes

Clinical Trial Report

Weight-Loss Diet Studies: Is the Most Rigorous Trial To Date Generalizable to Public Health?

Clinical Trial Report

Usual Versus “Tight” Blood Pressure Control: The Cardio-Sis Trial

ReviewPaper

Inflammation: The Link Between Obesity and Cardiovascular Risk

ReviewPaper

Nuclear Receptors in the Regulation of Lipid Metabolism

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen